Purpose of this Study
We are doing this study to monitor and keep track of the results when people who have HER2-positive metastatic breast cancer that has spread to the brain choose to get treatment with trastuzumab deruxtecan. This is an observational study, which means that the manner in which you are treated with this drug will not be affected by participating in the study.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with HER2-positive breast cancer
- Have cancer metastases (spread) to the brain
- Have a left ventricular ejection fraction of at least 50%
- Have been recommended to take trastuzumab deruxtecan by their doctor
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you choose to join this study, you will not need to make any special trips to our clinic. During some of your regularly scheduled routine visits, we will take an extra blood draw and ask you to fill out some questionnaires. We hope this information can help us learn more about how well trastuzumab deruxtecan works.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
Prospective Registry of Trastuzumab deruxtecan in Patients with Active/Progressive
HER2-Positive Breast Cancer Brain Metastases
HER2-Positive Breast Cancer Brain Metastases
Principal Investigator
Carey
Anders
Protocol Number
PRO00117026
Phase
N/A
Enrollment Status
Pending Open to Enrollment